Semi-Annual Consolidated Statement Of Cash Flows

Oncolys BioPharma Inc. - Filing #7342826

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
Semi-annual consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,935,578,000 JPY
-1,146,005,000 JPY
Depreciation
2,286,000 JPY
914,000 JPY
Impairment losses
21,898,000 JPY
4,403,000 JPY
Interest and dividend income
-1,478,000 JPY
-590,000 JPY
Interest expenses
3,602,000 JPY
3,945,000 JPY
Foreign exchange losses (gains)
-24,090,000 JPY
-72,723,000 JPY
Decrease (increase) in trade receivables
JPY
352,148,000 JPY
Decrease (increase) in inventories
18,907,000 JPY
-12,593,000 JPY
Other, net
20,812,000 JPY
-54,970,000 JPY
Subtotal
-1,359,074,000 JPY
-1,712,259,000 JPY
Interest and dividends received
616,000 JPY
553,000 JPY
Interest paid
-3,836,000 JPY
-3,962,000 JPY
Net cash provided by (used in) operating activities
-1,336,922,000 JPY
-1,717,135,000 JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-5,686,000 JPY
-1,358,000 JPY
Proceeds from sale of property, plant and equipment
136,000 JPY
JPY
Net cash provided by (used in) investing activities
-5,392,000 JPY
20,117,000 JPY
Cash flows from financing activities
Proceeds from long-term borrowings
100,000,000 JPY
100,000,000 JPY
Repayments of long-term borrowings
-194,444,000 JPY
-111,104,000 JPY
Proceeds from issuance of shares
1,223,450,000 JPY
JPY
Purchase of treasury shares
JPY
-28,000 JPY
Net cash provided by (used in) financing activities
1,142,542,000 JPY
-113,830,000 JPY
Effect of exchange rate change on cash and cash equivalents
21,334,000 JPY
67,413,000 JPY
Net increase (decrease) in cash and cash equivalents
-178,437,000 JPY
-1,743,434,000 JPY
Cash and cash equivalents
1,287,763,000 JPY
1,466,201,000 JPY
3,209,635,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.